InvestorsHub Logo
Followers 1
Posts 15
Boards Moderated 0
Alias Born 04/04/2017

Re: None

Wednesday, 05/24/2017 9:10:19 AM

Wednesday, May 24, 2017 9:10:19 AM

Post# of 9941
By the close of the quarter ending March 31, 2017, InMed was in a position to commence the optimization of the final formulation for INM-750,which will be followed by key pre-clinical toxicology (safety) studies. It is anticipated that InMed will be discussing its clinical development plans with regulatory bodies in late 2017/early 2018 and identifying clinical sites for the initial human clinical trial(s), which are expected to begin in the second half of 2018.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INM News